



10625221

C of C  
\$

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: SCHLIEVERT ET AL. Docket: 600.311USD1  
Patent No.: 6,870,042 B1  
Issued: MARCH 22, 2005  
Title: MUTANTS OF STREPTOCOCCAL TOXIN A AND METHODS OF USE

**CERTIFICATE UNDER 37 CFR 1.8:**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 7, 2005.

By: 

Name: Kristine A. Wacek

Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Transmittal Sheet in duplicate containing Certificate of Mailing
- ☒ Request for Certificate of Correction
- ☒ Certificate of Correction
- ☒ Check in the amount of \$100.00 for Certificate of Correction for Applicant's Errors
- ☒ Return postcard

Certificate  
JUL 14 2005  
of Correction

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

Merchant & Gould P.C.  
P.O. Box 2903 Minneapolis, MN 55402-0903  
612.332.5300

By: 

Name: Mark T. Skoog  
Reg. No.: 40,178  
MSkoog:PLSkaw

**23552**

PATENT TRADEMARK OFFICE

(PTO TRANSMITTAL - POST ISSUANCE)

JUL 15 2005



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent No.: 6,870,042 B1 Docket: 600.311USD1  
Issue Date: MARCH 22, 2005 Patentee: SCHLIEVERT ET AL.  
Title: MUTANTS OF STREPTOCOCCAL TOXIN A AND METHODS OF USE

CERTIFICATE UNDER 37 CFR 1.8:

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on July 7, 2005.

By: 

Name: Kristine A. Wacek

REQUEST FOR CERTIFICATE OF CORRECTION

Certificate of Correction Branch  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

**23552**

PATENT TRADEMARK OFFICE

Sir:

It is requested that a Certificate of Correction be issued correcting printing errors appearing in the above-identified United States patent. One copy of the text of the Certificate in the suggested form is enclosed.

As some of the errors listed are due to Applicant's mistake, our check in the amount of \$100.00 is enclosed to cover the Certificate fee.

Issuance of the Certificate of Correction would neither expand nor contract the scope of the claims, and re-examination is not required.

Respectfully submitted,


MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

07/12/2005 AAD0F01 00000053 6870042

01 FC:1811

100.00 DP

Date: July 7, 2005



Mark T. Skoog  
Reg. No. 40,178  
MTS:PLSkaw

JUL 15 2005

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO. :** 6,870,042 B1

**PAGE** 1 **of** 3

**DATED :** MARCH 22, 2005

**INVENTOR(S) :** SCHLIEVERT ET AL.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 1, line 10, insert the following paragraph:

--Government Support

This invention was made with government support under Grant No. HL36611 from the U.S. National Institutes of Health. The government has certain rights in the invention.--

Col. 2, line 2: "TNT- $\alpha$ " should read --TNF- $\alpha$ --

Col. 2, line 17: after "this pathology." insert the following sentence --Certain single amino acid substitutions in central regions of the SPE-A molecule have been shown to affect the mitogenic activity of and binding to a HLA class II molecules by SPE-A (Hartwig et. al. International Immunology 5:5, 869-875 (1993)).--

Col. 2, line 32: "to human umbilical" should read --to the human umbilical--

Col. 9, line 47: "useful in vaccine is" should read --useful in vaccine--

Col. 12, line 33: "wild is type SPEA." should read --wild type SPEA.--

Col. 13, line 47: "viva using fluorescence" should read --vivo using fluorescence--

Col. 14, line 7: "amino aced sequence" should read --amino acid sequence--

Col. 14, line 50: "wild type is SPE-A toxin" should read --wild type SPE-A toxin--

Col. 14, line 67: "Compostions or" should read --Compositions or--

Col. 16, line 67: "and 31 flanking" should read --and 3' flanking--

**MAILING ADDRESS OF SENDER:**

Merchant & Gould P.C.  
Attn: Mark T. Skoog  
P.O. Box 2903  
Minneapolis, MN 55402-0903

**PATENT NO.** 6,870,042 B1

**Docket No.** 600.311USD1

**No. of add'l copies** 0

**23552**

PATENT TRADEMARK OFFICE

JUL 15 2005

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO. :** 6,870,042 B1

**PAGE** 2 **of** 3

**DATED :** MARCH 22, 2005

**INVENTOR(S) :** SCHLIEVERT ET AL.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 18, line 39: "in Example S." should read --in Example 5.--

Col. 18, line 51: "with chances in amino acid" should read --with changes in amino acid--

Col. 22, line 49: "pBR328 (carrying Amp and" should read --pBR328 (carrying Amp and Tet--

Cols. 25-26, line 48:  
"5' -CCC CCC GTC GAC GAT AAA ATA GTT GCT AAG CTA CAA GCT-3' (SEQ ID NO:2)"  
Sal I  
should be in column 26 and not in column 25.

Col. 31, line 20: "The double is mutant genes" should read --The double mutant genes--

Col. 34, lines 5-6: "average titer with the titers" should read --average titer with the other two mutants being comparable. However, the range of titers--

Col. 45, line 11, claim 3: "fiber comprising a" should read --further comprising a--

Col. 46, line 16, claim 16: "ard encoding a polypeptide" should read --and encoding a polypeptide--

**MAILING ADDRESS OF SENDER:**

Merchant & Gould P.C.  
Attn: Mark T. Skoog  
P.O. Box 2903  
Minneapolis, MN 55402-0903

**PATENT NO.** 6,870,042 B1

**Docket No.** 600.311USD1

**No. of add'l copies** 0

**23552**

PATENT TRADEMARK OFFICE

**JUL 15 2005**

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

**PATENT NO. :** 6,870,042 B1

**PAGE** 3 **of** 3

**DATED :** MARCH 22, 2005

**INVENTOR(S) :** SCHLIEVERT ET AL.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Col. 46, line 17, claim 16: "wild-type SPEA toxin; or" should read --wild-type SPE-A toxin;  
or--

Col. 46, line 31, claim 19: "comprising apolynucleotide" should read --comprising a  
polynucleotide--

**MAILING ADDRESS OF SENDER:**

Merchant & Gould P.C.  
Attn: Mark T. Skoog  
P.O. Box 2903  
Minneapolis, MN 55402-0903

**PATENT NO.** 6,870,042 B1

**Docket No.** 600.311USD1

**No. of add'l copies** 0

**23552**

PATENT TRADEMARK OFFICE

**JUL 15 2005**